Through careful unraveling of the cellular and molecular landscape of prostate cancer, Massachusetts General Hospital researchers observed a highly immune-suppressive tumor microenvironment with a pattern of angiogenic gene expression, findings that will help identify targets amenable to therapeutic interventions.
Shenglin Mei, PhD, Philip J. Saylor, MD, David B. Sykes, MD, PhD, and colleagues found that simultaneous expression of four specific genes predicts survival and metastasis in human clear cell renal cell carcinoma, and they identified other potential therapeutic targets.
Shenglin Mei, PhD, is a research fellow in the Department of Medicine at Massachusetts General Hospital.
Mass General Bladder, Kidney, Penile, Prostate and Testicular Cancer Program
Physicians in the Mass General Bladder, Kidney, Penile, Prostate and Testicular Cancer Program specialize in using advanced surgical therapies and minimally invasive procedures to treat male and female genitourinary cancers.